nach oben

Erschienen in:

01.06.2019 | Case report

Nintedanib

Aspartate aminotransferase elevated: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study involving 142 patients, an 82-year-old¹ man was described, who developed elevated aspartate aminotransferase levels following treatment with nintedanib [route not stated] for idiopathic pulmonary fibrosis (IPF). The man had been diagnosed with IPF and started receiving treatment with nintedanib 100mg twice a day. The dose was further increased to 150mg, twice a day and he subsequently developed grade 2 elevated aspartate aminotransferase levels [duration of treatment to reaction onset not stated]. The man's nintedanib was reduced [outcome not stated]. …

Patient demographics obtained via e-mail communication with the author.

Ikeda S, et al. Low starting-dosage of nintedanib for the reduction of early termination. Respiratory Investigation 57: 282-285, No. 3, May 2019 - Japan

Titel: Nintedanib
Aspartate aminotransferase elevated: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64086-9

Springer Medizin

Nintedanib

Aspartate aminotransferase elevated: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Pramocaine

Rituximab

Abacavir

Sirolimus

DTaP vaccine

Bedaquiline/delamanid

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Pramocaine

Rituximab

Abacavir

Sirolimus

DTaP vaccine

Bedaquiline/delamanid